NCT01841125View on ClinicalTrials.gov

Escitalopram for the Treatment of Depression in Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Alzheimer's Disease
Interventions
DRUG

escitalopram

escitalopram 15mg, QD(once a day), Oral medication, 24weeks

DRUG

Placebo

placebo 15mg, QD(once a day), Oral medication

Trial Locations (1)

505

MedicalExcellence, Seoul

All Listed Sponsors
lead

Konkuk University Medical Center

OTHER

NCT01841125 - Escitalopram for the Treatment of Depression in Alzheimer's Disease | Biotech Hunter | Biotech Hunter